Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Debio 0123 plus sacituzumab govitecan in advanced/metastatic breast cancer
2024-516322-60-00Phase 2Suspended
- Sponsor
- MEDSIR
- Start
- Jan 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of zedoresertib and sacituzumab govitecan in breast cancer, triple-negative breast cancer (TNBC) and hormone receptor-positive/HER2-negative breast cancer, sponsored by MEDSIR. Started Jan 2025; status: suspended.
02
Drugs
zedoresertibsacituzumab govitecan
03
Conditions
breast cancertriple-negative breast cancer (TNBC)hormone receptor-positive/HER2-negative breast cancer
Beyond the preview
Go deeper on 2024-516322-60-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516322-60-00.